Beat
Biotech & Longevity
Drug trials, gene editing, and longevity — the science with the caveats intact.
July 2026
Saturday, 18 July 2026
You can now bet on whether a drug will pass its trial — and that quietly changes the trial
A prediction market opened contracts on clinical-trial results and FDA decisions, promising to surface truth the sponsors keep hidden. The same payoff hands a motive to anyone who can move or leak the result. Plus the first cholesterol pill of its kind, and a vaccine aimed at pancreatic cancer before it starts.
Friday, 17 July 2026
An Ebola trial was built in six weeks — while the outbreak's frontline collapses for lack of pay
A record-fast treatment trial and a new vaccine show what years of pooled preparation can do. Unpaid, attacked burial teams show how quickly coordination breaks at the bottom.
Thursday, 16 July 2026
The FDA is publishing the letters that say why drugs get rejected — and the industry is fighting it
For years a drug rejection was a private letter only the company saw. Now the FDA is posting them, and pharma has filed to stop it. Plus ADCs come for chemo, an Ebola trial races the outbreak, and a heart drug fails.
Wednesday, 15 July 2026
A drug slowed Alzheimer's by hitting the protein everyone ignored — and still "failed" its own test
Biogen's anti-tau drug diranersen slowed cognitive decline as well as approved medicines, with fewer risks — yet missed its primary trial goal, because the lowest dose worked best. Plus the Alzheimer's graveyard around it, and a fast-built Ebola vaccine heads into people.
Tuesday, 14 July 2026
Four children with "universally fatal" brain cancer are alive years after an experimental therapy
A small trial of a cell therapy kept children with incurable brain tumours alive for years — a phase 1 result, not a cure. Plus the FDA starts publishing its drug rejections again, and three big programs die.
Monday, 13 July 2026
A cancer therapy, taken off a shelf, is turning on the immune system that attacks itself
Fate's ready-made CAR-T shows early promise in a rare autoimmune disease — while $10B and $1.5B deals reshape the industry and Roche walks away from Huntington's.
Sunday, 12 July 2026
A quiet approval for a slow kidney disease — and an immune system we're learning to calm
The FDA cleared a new drug for IgA nephropathy, a disease that erases kidneys over decades. It sits inside a good week for immune medicine — off-the-shelf cell therapy easing hard autoimmune disease, a 40-year HIV vaccine problem yielding step by step — and a reminder that progress still doesn't reach everyone.
Saturday, 11 July 2026
Doctors have replaced the dopamine in Parkinson's for 60 years — now they're trying to replace the cells that make it
A Lund University trial put lab-grown dopamine cells into eight Parkinson's patients' brains and reported a clean first-year safety record — the first serious attempt to rebuild what the disease destroys rather than top it up. Plus: a hoped-for vaccine benefit collapses under a proper trial, and the FDA quietly stops publishing its drug-rejection letters.
Friday, 10 July 2026
Three big drug programs died this week — and the one that hurts most did everything it was designed to do
GSK, Roche and AstraZeneca all pulled the plug on programs for the hardest diseases. The Huntington's drug lowered the disease-causing protein exactly as planned — and patients still didn't get better.
Thursday, 9 July 2026
A gentler way to clear the bone marrow — and a KRAS lung-cancer race gets a new front-runner
Scientists found a way to prepare patients for a stem-cell transplant without burning down the whole body first. Plus: Roche's KRAS drug beats its two rivals, Novartis buys into a new cancer weapon, and the WHO says cancer progress is skipping the poor.
Wednesday, 8 July 2026
Big pharma spent billions this week buying biotechs it could have built
A run of deals — Vertex's $10bn Crinetics buyout, Novartis, Ipsen, United Therapeutics — shows the giants outsourcing early science to small firms and paying only for winners.
Tuesday, 7 July 2026
The new US health aid comes with strings — and some African governments are saying no
Washington is offering African nations billions to build their own health systems, but the money is tied to conditions on data, drugs, and minerals — and several countries are refusing while the WHO-run fight against Ebola in Congo carries on.
Monday, 6 July 2026
The pills that quietly erased obesity's heart-risk gap — and a UK weight-loss tablet hits the shelves
A large study finds statins and blood-pressure drugs have narrowed obesity's cardiovascular disadvantage to almost nothing, as a swallowable Wegovy reaches UK pharmacies. Plus a KRAS lung-cancer win, a rare-disease bone drug, and a vaccine for a parasite that infects 250 million people.
Sunday, 5 July 2026
The third company to crack an "undruggable" cancer target just beat the two that got there first
Roche's late-arriving lung-cancer drug outperformed Amgen's and Bristol Myers Squibb's in a head-to-head trial — the week's clearest lesson that being first proves a thing is possible, but rarely means you keep the prize.
Saturday, 4 July 2026
China clears the first CAR-T for a solid tumor — the wall cancer therapy has hit for 15 years
A Shanghai biotech won the world's first approval for a CAR-T therapy against a solid tumor, cracking a problem that has stopped the field since 2010 — plus an AI lab that now wants to make its own drugs, a 40-year-old cancer target finally cornered, and a clue to why some brains shrug off Alzheimer's.
Friday, 3 July 2026
The gene-editing drug that doesn't cut the gene — a muscle disease is the first test
A new kind of therapy changes what a gene does without altering the DNA itself. Early data in three patients with a muscular dystrophy is the first human sign it works. Plus China's first solid-tumor CAR-T, and a wave of rare-disease deals.
Thursday, 2 July 2026
The FDA delays a rare-epilepsy drug three months — and analysts blame last year's staff cuts
A finished drug application sits in a longer queue, as the agency that reviews it runs shorter on people. Plus a gene therapy chief steps down, and a busy week of new results piling up behind them.
Wednesday, 1 July 2026
The FDA seats a panel on wellness peptides — and most of the panelists sell them
A US committee that will decide whether pharmacies can make seven unproven peptides is now stacked with people who prescribe and profit from them. Plus a mechanism for how Alzheimer's spreads, and two more late-stage trial flops.
June 2026
Tuesday, 30 June 2026
A big fish-oil trial proves the pills reach the brain — and do nothing for it
Americans spend over $1bn a year on omega-3 supplements for memory. A two-year USC trial confirmed the omega-3 got into the brain, then found no benefit to memory or to the brain shrinkage that tracks Alzheimer's. The same week showed the wider pattern: demand for peptides and weight-loss drugs is racing ahead of the proof.
Monday, 29 June 2026
An LSD pill posts the best depression data the field has seen — and the hardest result to read
Definium's psychedelic drug beat placebo by 8.1 points in a phase 3 trial and sent its shares up 55%. The number is real; the trouble is that a drug which makes you trip can't be tested blind, so no one can fully separate the drug from the patient knowing they got it.
Sunday, 28 June 2026
The week age stopped meaning your birthday — and a body clock predicted cancer
A 154,000-person study found a generation's bodies are ageing faster than the calendar says, and that the gap predicts who gets cancer young. Plus a Yale study where half of older adults got better, not worse, and a family-tree hunt that narrowed the genes for a long healthy life from 20,000 to 12.
Saturday, 27 June 2026
Soil bacteria carry a built-in four-drug antibiotic cocktail — and it's hard to outrun
A single gene cluster in common soil bacteria makes four antibiotics at once, all hitting the same essential pathway in different places. Bacteria can dodge one drug; dodging four is far harder.
Friday, 26 June 2026
The company that invented gene editing went bankrupt the week the field had its biggest wins
Sangamo Therapeutics, which coined the term "genome editing" 20 years ago, filed for Chapter 11 — the same week a CRISPR rival posted a landmark trial and a man was cured of sickle cell. The pioneer built the road; the followers are driving it.
Thursday, 25 June 2026
A US company will sell an unproven anti-ageing gene therapy abroad to skip the FDA
Minicircle is about to offer a longevity gene therapy in Honduras, the Bahamas and Panama with no rigorous trials and no regulator's approval — while the field that plays by the rules saw real cures, real failures, and a pioneer go bankrupt.
Wednesday, 24 June 2026
The week three big drug bets failed — and what the winners' headlines hide
Pfizer, Exelixis and Novocure all saw late-stage trials fall short this week, even as the LSD pill and the $10.9bn deal grabbed the cheers. A normal week in biotech is mostly failure — we just rarely hear about it.
Tuesday, 23 June 2026
The week HIV funding shrank while $745m flowed into the drugs that pay
As the US cut money for HIV research and care, hundreds of millions poured into commercially attractive biotech — a snapshot of how funding, not need, decides which science advances.
Monday, 22 June 2026
AbbVie bets nearly $11bn on a biotech whose drugs aren't proven yet — and it wasn't alone this week
A wave of pharma dealmaking, led by AbbVie's roughly $11 billion move for Apogee Therapeutics, shows big drugmakers buying promising science years before it's certain to work.
Sunday, 21 June 2026
A one-time gene edit cut a rare disease's attacks by 87% — the first phase 3 proof that CRISPR works inside the body
Intellia's in-vivo CRISPR treatment for hereditary angioedema posted the first late-stage results for editing genes inside a living person. Plus the FDA's softer line on rare-disease gene therapy, a new antifungal as resistance climbs, and an $11bn deal.
Saturday, 20 June 2026
An mRNA flu shot goes to the FDA — and the math of giving anything to millions
A US advisory panel weighed Moderna's mRNA flu vaccine this week. The bigger story is what happens to rare risks and tiny benefits once a shot reaches tens of millions of arms.
Friday, 19 June 2026
The week the FDA changed its mind about what counts as proof
A gene therapy for Huntington's got a green light it was denied three months ago, on the same data — a reminder that the evidence bar for approval is a judgment call, not a fixed line, and the line moved this week.
Thursday, 18 June 2026
The week a 200,000-woman cancer screening trial finally explained why it failed
A near-perfect ovarian cancer test still saved no lives — a lesson in why a rare disease defeats even an accurate screen. Plus a prenatal blood test reads 23,000 genes, an AI flags a clot a doctor missed, and HPV shots push cervical-cancer death toward zero.
Wednesday, 17 June 2026
A depression drug just lost to a sugar pill three times in a row
Neumora's navacaprant failed its third and final late-stage depression trial — in one study, patients on the placebo did better. The week's other results show what beating a sugar pill actually looks like.
Tuesday, 16 June 2026
Scientists edited the red out of lettuce — and other compounds quietly took its place
A gene edit switched off red lettuce's pigment, but the molecules it was made from didn't vanish. They piled up and poured into a different compound instead, with the plant growing normally — a vivid reminder that you can't subtract one thing from a living system, only redirect it.
Monday, 15 June 2026
The week a therapy to make old cells young again was put into a person for the first time
Life Biosciences dosed the first patient in a trial that switches on three genes to partially rewind ageing cells — starting, carefully, in the eye. Plus off-the-shelf CAR-T matches the bespoke kind, a $10.6bn cancer buyout, and a drug to stop immunotherapy's deadliest side effect.
Sunday, 14 June 2026
The week the weight-loss drugs admitted what "weight" leaves out
A new trial, a wearable study, and a string of conference data all circled the same blind spot in the obesity-jab boom — the scale can't tell muscle from fat, and a third of the loss is the wrong kind.
Saturday, 13 June 2026
A cancer therapy just put five lupus patients into remission — and it points at a dozen more diseases
A one-time treatment built to kill blood cancer reset the immune systems of patients with severe lupus. The same tool is now being aimed at MS and rheumatoid arthritis.